NCBI PubMed Central
open access
Navigating the Challenges of Shared Decision-Making in Amyloid Immunotherapy for Alzheimer's Disease.
Background Anti-amyloid therapies (AATs), such as lecanemab and donanemab, represent a major therapeutic development for early Alzheimer's disease (AD). However, safety risks and uncertainties regarding long-term effects make treatment decisions complex. These decisions arise when patients r
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- AN INVESTIGATION INTO THE NEUROPROTECTIVE POTENTIAL OF ERGOTHIONEINE IN THE AMYLOID HYPOTHESIS OF ALZHEIMER’S DISEASE#254779
- Overcoming the Blood-Brain Barrier for Targeted Drug Delivery in Neurological Diseases#77767
- Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)#1282680
- A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients#966354
- Safety Study of Abatacept in Rheumatoid Arthritis Participants#1483872
Record · ID 1538547
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive